Roche stock holds firm after half-year sales reached CHF 30.4 billion
Published on 08/22/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding AG (CH0012032048) is being priced against CHF 30.4 billion in first-half 2026 sales and a Swiss close of CHF 375.60 on August 21, 2026.
The company's half-year update on Roche's investor page says sales rose 6% at constant exchange rates in the first six months of 2026, while the same update puts dividend yield for FY 2025 at 3.2% and the next report at October 22, 2026.
Sales and valuation
That pairing matters for Roche shares because the current quote set also shows a market capitalization of $371.39 billion and a one-year gain of 40.78% on the same Swiss line, with the latest Deutsche Boerse quote at EUR 406.00 and +1.35% on August 21, 2026.
On the trading screen, the Swiss line closed at CHF 375.60, the 52-week high stands at CHF 418, and the 52-week low is CHF 283.40. The stock has also gained 11.29% in 2026 and 5.24% over one week.
What changed in the half-year
The half-year sales figure of CHF 30.4 billion is the most important current operating number, and the 6% CER growth rate gives investors a simple comparison with the prior-year base. It also helps explain why Roche still trades with a large market value despite a six-month performance of -0.20% on the Swiss line.
Volume context is equally notable: the Swiss line showed 7.65M CHF of volume on the quoted session, while the OTC line RHHBY traded at $58.10 and up 1.48% on August 21, 2026. The market is still giving Roche a premium valuation rather than a distressed one.
More on Roche's business
Roche combines pharmaceuticals and diagnostics, and the company page highlights both as the core of its business model. The half-year result sits inside that mix, with the investor page emphasizing sales growth rather than a margin breakdown.
Roche shares on the screen
Roche shares ended the latest completed Swiss session at CHF 375.60, while the OTC Markets line for RHHBY stood at $58.10 and the market cap was $371.39 billion. That leaves the stock within a broad range but still well above the year low of CHF 283.40.
Investor information
Company: Roche Holding AG
ISIN: CH0012032048
Ticker: ROP
Exchange: Swiss Exchange
Price (as of August 21, 2026): CHF 375.60
Market cap: $371.39 billion
Sector / Industry: Pharmaceuticals / Pharmaceuticals and diagnostics
Index membership: SMI
Next earnings date: October 22, 2026
